Nina Bhardwaj
#112,910
Most Influential Person Now
Researcher
Nina Bhardwaj's AcademicInfluence.com Rankings
Nina Bhardwajengineering Degrees
Engineering
#3321
World Rank
#4378
Historical Rank
Biomedical Engineering
#151
World Rank
#154
Historical Rank
Applied Physics
#590
World Rank
#610
Historical Rank
Nina Bhardwajbiology Degrees
Biology
#6354
World Rank
#9046
Historical Rank
Immunology
#328
World Rank
#341
Historical Rank
Download Badge
Engineering Biology
Nina Bhardwaj's Degrees
- PhD Biomedical Engineering Stanford University
- Masters Biomedical Engineering Stanford University
- Bachelors Biomedical Engineering Stanford University
Why Is Nina Bhardwaj Influential?
(Suggest an Edit or Addition)Nina Bhardwaj's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs (1998) (2584)
- Consequences of cell death: exposure to necrotic tumor cells (2000) (1528)
- Antigen-Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature Dendritic Cells (2001) (1511)
- Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes (1998) (1368)
- Immunology of COVID-19: Current State of the Science (2020) (1293)
- Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. (2001) (892)
- Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. (1996) (751)
- Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. (2016) (734)
- Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells (1998) (722)
- Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. (1994) (709)
- Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. (2005) (696)
- Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. (2016) (567)
- Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor (2009) (550)
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments (2018) (543)
- Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. (1999) (487)
- Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium (1993) (431)
- Tumor-specific killer cells in paraneoplastic cerebellar degeneration (1998) (430)
- Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity (2005) (407)
- Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. (1999) (405)
- Phenotypic properties of transmitted founder HIV-1 (2013) (389)
- Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. (2003) (385)
- Human Immunodeficiency Virus Type 1 Activates Plasmacytoid Dendritic Cells and Concomitantly Induces the Bystander Maturation of Myeloid Dendritic Cells (2004) (383)
- Dendritic cell-based immunotherapy (2016) (357)
- Manipulating dendritic cell biology for the active immunotherapy of cancer. (2004) (355)
- Combining radiotherapy and immunotherapy: a revived partnership. (2005) (337)
- CD8 Epitope Escape and Reversion in Acute HCV Infection (2004) (333)
- miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. (2011) (325)
- Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival (2009) (316)
- Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming (2007) (312)
- Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. (1994) (292)
- A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. (1997) (289)
- A conserved dendritic-cell regulatory program limits antitumour immunity (2020) (287)
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade (2014) (280)
- Primary Tumor Tissue Lysates Are Enriched in Heat Shock Proteins and Induce the Maturation of Human Dendritic Cells1 (2001) (276)
- Efficient Interaction of HIV-1 with Purified Dendritic Cells via Multiple Chemokine Coreceptors (1996) (270)
- Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA (2005) (267)
- Therapeutic cancer vaccines (2021) (262)
- Multiple forms of IFN-beta 2/IL-6 in serum and body fluids during acute bacterial infection. (1989) (260)
- Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1 (2008) (237)
- A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. (1999) (236)
- HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. (2008) (232)
- A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer (2020) (231)
- Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. (1993) (221)
- DCs and NK cells: critical effectors in the immune response to HIV-1 (2011) (219)
- Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. (2000) (218)
- A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. (2002) (210)
- Dendritic cells resurrect antigens from dead cells. (2001) (202)
- The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. (2005) (196)
- Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction (2020) (194)
- Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. (2018) (190)
- Evidence of dysregulation of dendritic cells in primary HIV infection. (2010) (185)
- LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. (2010) (185)
- Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer (2012) (184)
- Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses (1995) (179)
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer (2018) (177)
- Selective Loss of Innate CD4+ Vα24 Natural Killer T Cells in Human Immunodeficiency Virus Infection (2002) (168)
- Interferon-gamma-activated human monocytes inhibit the intracellular multiplication of Legionella pneumophila. (1986) (161)
- Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses (1993) (159)
- Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. (2003) (154)
- The Human Vaccines Project: A roadmap for cancer vaccine development (2016) (151)
- Requirement of Mature Dendritic Cells for Efficient Activation of Influenza A-Specific Memory CD8+ T Cells1 (2000) (147)
- Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy: A Pilot Study (2013) (137)
- Harnessing the immune system to treat cancer. (2007) (136)
- Toll-Like Receptor Agonists: Are They Good Adjuvants? (2010) (136)
- Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. (1999) (135)
- EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. (2001) (132)
- Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. (2011) (131)
- Danger signals: a time and space continuum. (2004) (125)
- The distinctive features of influenza virus infection of dendritic cells. (1998) (125)
- Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus (2002) (125)
- IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. (1996) (125)
- Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. (2007) (119)
- Directing dendritic cell immunotherapy towards successful cancer treatment. (2010) (119)
- IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources. (1989) (112)
- The apoptotic cell receptor CR3, but not αvβ5, is a regulator of human dendritic cell immunostimulatory function (2006) (112)
- Dendritic cells as targets for therapy in rheumatoid arthritis (2009) (110)
- Dendritic cell subsets and locations. (2019) (108)
- Human Immunodeficiency Virus Type 1 Modified To Package Simian Immunodeficiency Virus Vpx Efficiently Infects Macrophages and Dendritic Cells (2011) (108)
- CD8+ T Cell Priming by Dendritic Cell Vaccines Requires Antigen Transfer to Endogenous Antigen Presenting Cells (2010) (103)
- Efficiency of cross presentation of vaccinia virus‐derived antigens by human dendritic cells (2001) (103)
- Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Vα24 NKT cell compartment (2003) (101)
- The Anergic State in Sarcoidosis Is Associated with Diminished Dendritic Cell Function1 (2008) (101)
- Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties (2013) (101)
- Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells. (2001) (98)
- Dendritic cells are potent antigen-presenting cells for microbial superantigens (1992) (97)
- Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial (2014) (95)
- Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. (2017) (94)
- Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells (1998) (93)
- Tethering and tickling (2001) (92)
- Dendritic cells in progression and pathology of HIV infection. (2014) (91)
- Dendritic cell dysregulation during HIV‐1 infection (2013) (90)
- Recent Advances in Dendritic Cell Biology (2005) (89)
- CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases (2011) (89)
- A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. (2009) (87)
- MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin (2011) (87)
- Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. (1999) (87)
- Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity (2018) (86)
- Generation of monocyte-derived dendritic cells from precursors in rhesus macaque blood. (1997) (85)
- Processing and presentation of antigens by dendritic cells: implications for vaccines. (2001) (82)
- Interactions of Viruses with Dendritic Cells: A Double-edged Sword (1997) (82)
- Mature Dendritic Cells Infected with Canarypox Virus Elicit Strong Anti-Human Immunodeficiency Virus CD8+and CD4+ T-Cell Responses from Chronically Infected Individuals (2001) (81)
- Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. (2019) (80)
- Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial (2018) (78)
- Reversal of natural killer cell exhaustion by TIM-3 blockade (2014) (77)
- Apoptotic cells at the crossroads of tolerance and immunity. (2005) (77)
- Cancer immunotherapy: Dendritic-cell vaccines on the move (2015) (73)
- Phosphorylation of secreted forms of human beta 2-interferon/hepatocyte stimulating factor/interleukin-6. (1988) (73)
- Lack of Phenotypic and Functional Impairment in Dendritic Cells from Chimpanzees Chronically Infected with Hepatitis C Virus (2004) (72)
- Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma (2015) (72)
- Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors (2020) (72)
- Recent advances in dendritic cell biology. (2005) (71)
- Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. (1999) (70)
- Plasmacytoid dendritic cells in HIV infection. (2013) (69)
- Intravenous Nanoparticle Vaccination Generates Stem-Like TCF1+ Neoantigen-Specific CD8+ T Cells (2020) (69)
- Towards superior dendritic-cell vaccines for cancer therapy (2018) (68)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- Quantitative Effect of Suboptimal Codon Usage on Translational Efficiency of mRNA Encoding HIV-1 gag in Intact T Cells (2008) (67)
- Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs (2021) (66)
- Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma (2009) (66)
- DC-virus interplay: a double edged sword. (2004) (66)
- Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node (2012) (65)
- Intraepidermal lymphocytes in psoriatic lesions are activated GMP‐17(TIA‐1)+CD8+CD3+ CTLs as determined by phenotypic analysis (1998) (64)
- Activation of the noncanonical NF-κB pathway by HIV controls a dendritic cell immunoregulatory phenotype (2012) (63)
- Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. (2002) (62)
- In situ vaccination for the treatment of cancer. (2016) (62)
- Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. (2006) (61)
- Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes (2017) (61)
- Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial (2016) (60)
- Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. (1999) (59)
- Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells (2015) (59)
- Oligonucleotide Motifs That Disappear during the Evolution of Influenza Virus in Humans Increase Alpha Interferon Secretion by Plasmacytoid Dendritic Cells (2011) (59)
- Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. (2014) (58)
- Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. (2019) (57)
- Type I interferons promote cross-priming: more functions for old cytokines (2003) (57)
- Modulation of innate immunity in the tumor microenvironment (2016) (57)
- Computational Prediction and Validation of Tumor-Associated Neoantigens (2020) (57)
- Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. (2008) (56)
- TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. (2011) (56)
- Presentation of Epstein‐Barr virus latency antigens to CD8+, interferon‐γ‐secreting, T lymphocytes (1999) (55)
- Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway. (2011) (54)
- In Vitro Priming Recapitulates In Vivo HIV-1 Specific T Cell Responses, Revealing Rapid Loss of Virus Reactive CD4+ T Cells in Acute HIV-1 Infection (2009) (54)
- Dendritic cell immunotherapy (2013) (53)
- Cross-presentation of cell-associated antigens by dendritic cells. (2003) (53)
- Advancing scientific knowledge in times of pandemics (2020) (52)
- HIV type 1 infection of plasmacytoid and myeloid dendritic cells is restricted by high levels of SAMHD1 and cannot be counteracted by Vpx. (2014) (49)
- The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. (2006) (48)
- Pathways utilized by dendritic cells for binding, uptake, processing and presentation of antigens derived from HIV‐1 (2007) (48)
- Innate immune responses in primary HIV-1 infection (2008) (47)
- Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells (2002) (47)
- Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma (2021) (46)
- HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. (2012) (46)
- Sequence-Specific Sensing of Nucleic Acids. (2017) (45)
- HIV-1 impairs in vitro priming of naïve T cells and gives rise to contact-dependent suppressor T cells (2010) (45)
- Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma (2019) (45)
- Computational Pipeline for the PGV-001 Neoantigen Vaccine Trial (2017) (44)
- Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. (2009) (43)
- Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. (2010) (43)
- Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. (2017) (42)
- Hematopoietic Progenitor Kinase 1 Is a Negative Regulator of Dendritic Cell Activation (2009) (42)
- Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. (2000) (42)
- Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm. (2000) (41)
- Interleukin 1 production during accessory cell-dependent mitogenesis of T lymphocytes (1989) (40)
- Interleukin-1 production by mononuclear cells from rheumatoid synovial effusions. (1988) (40)
- Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. (2017) (40)
- Resolution of immune activation defines nonpathogenic SIV infection. (2009) (40)
- Tethering and tickling: a new role for the phosphatidylserine receptor (2001) (39)
- Active Immunization of Humans with Dendritic Cells (2000) (39)
- Poly-ICLC, a TLR3 Agonist, Induces Transient Innate Immune Responses in Patients With Treated HIV-Infection: A Randomized Double-Blinded Placebo Controlled Trial (2019) (39)
- Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets (2020) (37)
- Spatial CRISPR genomics identifies regulators of the tumor microenvironment (2022) (37)
- Clinical relevance of Neutral Endopeptidase (NEP/CD10) in melanoma (2007) (37)
- Presentation of mycobacterial antigens by human dendritic cells: lack of transfer from infected macrophages (1993) (37)
- Dendritic cells efficiently immunoselect mycobacterial-reactive T cells in human blood, including clonable antigen-reactive precursors. (1992) (36)
- Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cells (2015) (36)
- Differentiation of Peripheral Blood Monocytes into Dendritic Cells (2005) (36)
- Activation of toll-like receptor-2 by endogenous matrix metalloproteinase-2 modulates dendritic-cell-mediated inflammatory responses. (2014) (36)
- Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function (2013) (35)
- KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. (2008) (34)
- Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. (2016) (34)
- Plasma Factors During Chronic HIV-1 Infection Impair IL-12 Secretion by Myeloid Dendritic Cells via a Virus-Independent Pathway (2012) (33)
- Current Melanoma Treatments: Where Do We Stand? (2021) (31)
- Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. (2022) (30)
- Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma (2019) (29)
- Landscape of natural killer cell activity in head and neck squamous cell carcinoma (2020) (28)
- AACR Cancer Progress Report 2015 (2015) (28)
- Dendritic Cell–Dead Cell Interactions: Implications and Relevance for Immunotherapy (2001) (27)
- Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. (2005) (27)
- P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1β in a Human Tonsil Explant Model (2018) (27)
- A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab (2018) (26)
- Vaccination With a Recombinant Protein Encoding the Tumor-specific Antigen NY-ESO-1 Elicits an A2/157-165-specific CTL Repertoire Structurally Distinct and of Reduced Tumor Reactivity Than That Elicited by Spontaneous Immune Responses to NY-ESO-1-expressing Tumors (2009) (26)
- Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer. (2020) (25)
- CSF1R Inhibition Depletes Tumor-Associated Macrophages and Attenuates Tumor Progression in a Mouse Sonic Hedgehog-Medulloblastoma Model (2020) (25)
- The Sensitization Phase of T‐Cell‐Mediated Immunity a (1988) (25)
- Cancer Immunotherapy Highlights from the 2014 ASCO Meeting (2014) (25)
- Residual Viral Replication during Antiretroviral Therapy Boosts Human Immunodeficiency Virus Type 1-Specific CD8+ T-Cell Responses in Subjects Treated Early after Infection (2002) (25)
- Vaccination with Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR52b-restricted CD4+ T Cell Responses with a Conserved T Cell Receptor Repertoire (2009) (25)
- Efficient in vitro expansion of JC virus-specific CD8(+) T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy. (2009) (24)
- Innate immune cells in the tumor microenvironment. (2021) (24)
- CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells (2016) (24)
- Dendritic Cell-Targeted Approaches to Modulate Immune Dysfunction in the Tumor Microenvironment (2013) (24)
- Dendritic cell amplification of HIV type 1-specific CD8+ T cell responses in exposed, seronegative heterosexual women. (2002) (23)
- Human T-cell responses to Mycoplasma arthritidis-derived superantigen (1994) (23)
- Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy (2015) (22)
- A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer. (2018) (22)
- A division of labor: DC subsets and HIV receptor diversity (2002) (21)
- Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. (2005) (21)
- A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles (2020) (21)
- HLA Class I–Associated Immunodominance Affects CTL Responsiveness to an ESO Recombinant Protein Tumor Antigen Vaccine (2009) (20)
- Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy (2014) (19)
- Modulation of human Th17 cell responses through complement receptor 3 (CD11 b/CD18) ligation on monocyte-derived dendritic cells. (2018) (19)
- Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines (2021) (19)
- Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. (2013) (18)
- Erratum: Recent Advances in Dendritic Cell Biology (2005) (18)
- Stimulation of human anti-viral CD8+ cytolytic T lymphocytes by dendritic cells. (1995) (18)
- Exploiting dendritic cells for active immunotherapy of cancer and chronic infections (2007) (18)
- Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. (2004) (17)
- Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation (2021) (17)
- Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection (2015) (17)
- MMP2 and TLRs modulate immune responses in the tumor microenvironment (2021) (17)
- Topical TLR 7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer (2012) (17)
- Vpx-containing Dendritic Cell Vaccine Vectors Induce CTLs and Reactivate Latent HIV-1 in vitro (2015) (16)
- Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab (2017) (15)
- Dendritic cells and the promise of therapeutic vaccines for human immunodeficiency virus (HIV)-1. (2003) (15)
- Consequences of Cell Death (2000) (15)
- Hair depigmentation as an indicator of durable response to CTLA-4 therapy. (2010) (15)
- Immunotherapy for AIDS virus infections: Cautious optimism for cell-based vaccine (2003) (14)
- A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. (2016) (13)
- Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing (2020) (13)
- Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial (2022) (12)
- Vaccines for immunoprevention of cancer. (2021) (12)
- Unexplored horizons of cDC1 in immunity and tolerance. (2020) (12)
- Interaction of Mycoplasma arthritidis superantigen with human T cells. (1993) (12)
- Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer (2018) (12)
- Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab (2017) (12)
- New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy (2019) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- A needle in the 'cancer vaccine' haystack (2010) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy (2021) (11)
- Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells. (2013) (11)
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments (2018) (10)
- Dendritic cells in human blood and synovial exudates. (1990) (10)
- Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus. (2015) (10)
- NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. (2022) (10)
- Mutation-Derived Tumor Antigens: Novel Targets in Cancer Immunotherapy. (2015) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Antigen-specific activity of murine leukocyte dialysates containing transfer factor on human leukocytes in the leukocyte migration inhibition (LMI) assay. (1981) (10)
- Widespread immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors (2019) (10)
- EBNA 1-specific CD 4 + T cells in healthy carriers of Epstein-Barr virus are primarily Th 1 in function (2000) (9)
- Dendritic cells as immunogens for human CTL responses. (1997) (9)
- An approach to isolating T cell lines that react to antigens presented on the surface of dendritic cells (1991) (9)
- Cross-Presentation of Tumor Antigens Is Ruled by Synaptic Transfer of Vesicles among Dendritic Cell Subsets. (2020) (9)
- Activation and measurement of NLRP3 inflammasome activity using IL-1β in human monocyte-derived dendritic cells. (2014) (9)
- Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing (2021) (9)
- PD-1 inhibition in advanced myeloproliferative neoplasms (2021) (9)
- Biology of plasmacytoid dendritic cells and natural killer cells in HIV-1 infection (2007) (8)
- Against the self: dendritic cells versus cancer (2003) (8)
- Converting tumors into vaccine manufacturing factories: DC recruitment, activation and clinical responses with a flt3L-primed in situ vaccine for low-grade lymphoma [nct01976585] (2014) (8)
- Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases. (2014) (8)
- Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). (2015) (8)
- Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. (2017) (8)
- Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. (2015) (8)
- Advances in dendritic cell immunotherapies for HIV-1 infection (2014) (8)
- Tolerizing mice to human leukocytes: a step toward the production of monoclonal antibodies specific for human dendritic cells. (1993) (8)
- Y-RNAs Lead an Endogenous Program of RIG-I Agonism Mobilized upon RNA Virus Infection and Targeted by HIV (2019) (8)
- Antigen depots: T cell traps? (2013) (8)
- Dysregulation of anti-tumor immunity by the matrix metalloproteinase-2 (2012) (8)
- Super(antigen) target for SARS-CoV-2 (2021) (8)
- Comparison of the immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines. (2009) (8)
- Armed and ready: How effector T cells deploy in reactive lymph nodes to modulate immunity (2007) (7)
- Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis (2018) (7)
- Abstract LB-194: First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results (2019) (7)
- Tim-3 and TIGIT mark Natural Killer cells susceptible to effector dysfunction in human bladder cancer (2018) (7)
- Dendritic Cell Vaccines. (2016) (7)
- Lack of functionally active Melan-A(26-35)-specific T cells in the blood of HLA-A2+ vitiligo patients. (2008) (7)
- Allelic variants of human TCR BV17S1 defined by restriction fragment length polymorphism, single strand conformation polymorphism, and amplification refractory mutation system analyses. (1996) (7)
- Interaction of subpopulations of murine lymph node lymphocytes in antigen-induced [14C]-thymidine incorporation: T and B cell synergy in the response to antigen. (1979) (6)
- TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. (2020) (6)
- Interferon-gamma and antibiotics fail to act synergistically to kill Legionella pneumophila in human monocytes. (1988) (6)
- A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. (2017) (6)
- 405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3) (2020) (6)
- Abstract CT125: A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broadde novoanti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer (2018) (6)
- Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1 (2022) (6)
- A MURINE MODEL FOR STUDYING THE TRANSFER OF DTH WITH DIALYSABLE HUMAN TRANSFER FACTOR1 (1979) (5)
- Turning a Tumor into a Vaccine Factory: In Situ Vaccination for Low-Grade Lymphoma (2014) (5)
- Author Correction: A conserved dendritic-cell regulatory program limits antitumour immunity (2020) (5)
- The effect of ipilimumab on natural killer cells identifies the subset of advanced melanoma patients with clinical response. (2015) (5)
- Immune Checkpoint Blockade Enhances Mutated Calreticulin-Induced T Cell Immunity in Myeloproliferative Neoplasms (2017) (5)
- DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC). (2017) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma. (2014) (5)
- Strategies to overcome DC dysregulation in the tumor microenvironment (2022) (5)
- CHAPTER 36 – Interactions of viruses with dendritic cells (2001) (4)
- Perturb-map enables CRISPR genomics with spatial resolution and identifies regulators of tumor immune composition (2021) (4)
- The Role and Mechanism of Action of Dendritic Cells in Transplantation Immunity (1986) (4)
- In situ vaccine for low-grade lymphoma: Combination of intratumoral Flt3L and poly-ICLC with low-Dose radiotherapy. (2015) (4)
- Chapter 9 – Dendritic Cells: General Overview and Role in Autoimmunity (2017) (4)
- A new data-driven cell population discovery and annotation method for single-cell data, FAUST, reveals correlates of clinical response to cancer immunotherapy (2019) (4)
- Mitogenic and adjuvant properties of the LPS-like component of Listeria monocytogenes (1981) (4)
- Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients (2021) (4)
- Plasmacytoid dendritic cells lead the charge against tumors. (2012) (4)
- TRANSFER OF DTH TO SK-SD AND TETANUS TOXOID IN BALB/c MICE BY TFd PREPARED FROM PURIFIED SUBPOPULATIONS OF MURINE LYMPHOCYTES1 (1979) (4)
- A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission. (2019) (3)
- CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients. (2005) (3)
- Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors. (2017) (3)
- Abstract 5410: Tim-3 expression and function in natural killer cells from metastatic melanoma patients (2012) (3)
- HIV-1 infection – induced apoptotic microparticles inhibit human DCs via CD 44 (2012) (3)
- A T-cell-based immunogenicity protocol for evaluating human antigen-specific responses (2021) (3)
- The modulation of immunity by dendritic cells (2003) (3)
- HIV-1 modified to package SIV Vpx efficiently infects 2 macrophages and dendritic cells (2011) (3)
- A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer. (2018) (3)
- Abstract 4745: Tim-3 and TIGIT mark NK and T cells susceptible to effector dysfunction in human bladder cancer (2018) (3)
- Preclinical Development of a Cord Blood (CB)-Derived Hematopoietic Stem Cell (HSC) Product for Allogeneic Transplantation in Patients with Hematological Malignancies (2016) (3)
- Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (3)
- Dendritic cell function in HIV infection (2009) (3)
- A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies. (2019) (2)
- Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine (2022) (2)
- Harnessing Natural Killer Cell Function for Genitourinary Cancers. (2020) (2)
- Dark genome, bright ideas: Recent approaches to harness transposable elements in immunotherapies. (2022) (2)
- Killed but Metabolically Active Recombinant Listeria monocytogenes as an Antigen Delivery and Activation Platform for Human Dendritic Cell-Based Cancer Immunotherapy. (2004) (2)
- Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma (2013) (2)
- Abstract B058: Expansion and activation of CD103+ DC progenitors at the tumor site promote T cell accumulation in melanoma lesions and transform clinical response to BRAF and PD-L1 blockade (2016) (2)
- Exhausted T cell phenotypes depend on TCR signal strength (2022) (2)
- Cellular immune responses against CT 7 ( MAGE-C 1 ) and humoral responses against other cancer-testis antigens in multiple myeloma patients (2005) (2)
- Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. (2012) (2)
- Intratumoral checkpoint subversion as a strategy for minimizing adverse effects (2014) (2)
- Correlation of consistent blood-based gene expression with change in CTLA4 in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab. (2017) (2)
- Impact of chemotherapy alone, and chemotherapy plus ipilimumab, on circulating immune cells in patients with metastatic bladder cancer (2015) (2)
- P2X antagonists inhibit HIV-1 productive infection and inflammatory cytokines IL-10 and IL-1β in a human tonsil explant model (2018) (2)
- Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma. (2014) (2)
- Correction Efficiency of cross presentation of vaccinia virus‐derived antigens by human dendritic cells (2002) (2)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (2)
- A method for eliciting indurated DTH reactions to soluble protein antigens in the flank skin of mice: correlation of visual measurements with 125I-UdR uptake indices. (1981) (2)
- Abstract B015: Expansion and activation of CD103+dendritic cell progenitors at the tumor site transform tumor response to PD-L1 and BRAF inhibition (2016) (2)
- In situ, therapeutic vaccination against refractory solid cancers with intratumoral Poly-ICLC: A phase I study. (2016) (2)
- TRANSFER OF CUTANEOUS DTH WITH HUMAN TFd TO BALB/c MICE: PARTIAL PURIFICATION OF ACTIVE COMPONENTS1 (1979) (1)
- Abstract CT062: A Phase I study of the safety and immunogenicity of personalized mutation-derived tumor vaccine and treatment fields in patients with newly diagnosed glioblastoma (2019) (1)
- Evaluation of toll-like receptor (TLR)-7 agonist imiquimod applied topically to breast cancer chest wall recurrences or skin metastases. (2010) (1)
- Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer (2022) (1)
- CT7 (MAGE-C1) is a widely expressed Cancer-Testis antigen in multiple myeloma. (2004) (1)
- Imiquimod: A TLR-7 agonist as adjuvant for a recombinant protein cancer vaccine (2007) (1)
- Treatment of solid tumors with intratumoral poly-ICLC: A phase II clinical study. (2014) (1)
- Differential Expression of Type I MAGE in New and Relapsed Multiple Myeloma: Evidence for Association with Proliferation and Progression of Disease. (2006) (1)
- Abstract CT108: Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence (2022) (1)
- Dendritic cell chic (2004) (1)
- Through the Fas ( CD 95 / APO-1 ) Pathway Dendritic Cells Are Resistant to Apoptosis Elkon (1999) (1)
- Influenza, but not HIV‐specific CTL epitopes, elicits delayed‐type hypersensitivity (DTH) reactions in HIV‐infected patients (2013) (1)
- Abstract 4862: Reversal of NK cell exhaustion in advanced melanoma patients by Tim-3 blockade (2014) (1)
- Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy (2014) (1)
- Tim-3 expression and function in natural killer cells from advanced melanoma patients. (2012) (1)
- Tumor organoid-originated biomarkers predict immune response to PD-1 blockade. (2021) (1)
- Essential Clinical Immunology: Immune Regulation (2009) (1)
- Dendritic cells and lymphoma cells: come together right now. (2015) (1)
- Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment (2021) (1)
- Spontaneous immune responses to melanoma-associated antigens in melanoma, vitiligo and healthy controls (2005) (1)
- CTIM-17. PHASE I STUDY OF THE SAFETY AND IMMUNOGENICITY OF PERSONALIZED NEOANTIGEN VACCINES AND TUMOR TREATING FIELDS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2020) (1)
- 621 NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients (2021) (1)
- Abstract A022: Computational pipeline for a personalized genomic vaccine trial (2016) (1)
- Identification and Characterization of Interleukin‐6/Interferon‐β2 in Synovial Effusions of Patients with Rheumatoid Arthritis and Other Arthritides (1989) (1)
- The immune response to HIV (2012) (1)
- Comprehensive immune profiling of patients with urothelial carcinoma of the bladder identifies a novel immune target (2017) (1)
- A new interpretable machine learning approach for single-cell data discovers correlates of clinical outcome in cancer immunotherapy (2020) (1)
- Uptake and presentation of phagocytosed antigens by dendritic cells (1999) (1)
- dendritic cell immunostimulatory function 5, is a regulator of human β v α The apoptotic cell receptor CR3, but not (2013) (1)
- Abstract LB048: An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001) (2021) (1)
- Towards superior dendritic-cell vaccines for cancer therapy (2018) (1)
- MMP-2: A novel target for antitumor immune therapy. (2016) (1)
- Trials in progress: A phase II study of in situ therapeutic vaccination against refractory solid cancers with intratumoral poly-ICLC. (2017) (1)
- Association of melanoma expression of matrix metalloproteinase-23 with blunted tumor immunity and poor responses to immunotherapy. (2015) (1)
- Abstract CT173: PGV-001: A phase I trial of a multipeptide personalized neoantigen vaccine in the adjuvant setting (2020) (1)
- Preliminary results from a first-in-human phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 (2018) (1)
- A bloody mess: dendritic cells use hemophagocytosis to regulate viral inflammation. (2013) (1)
- Abstract IA03: Turning a tumor into a vaccine factory: In situ vaccination for low-grade lymphoma (2015) (1)
- Abstract B207: Nivolumab +/- Ipilimumab in patients with hypermutated cancers detected in blood: NIMBLE (2019) (1)
- Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021 (2022) (1)
- Host Immune Responses Against CT Antigens in Multiple Myeloma Patients. (2006) (1)
- Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms (2020) (1)
- 337 Intratumoral immune therapy for recurrent breast cancer with polyICLC, and tremelimumab combined with systemic durvalumab (2021) (1)
- for plasmacytoid dendritic cells in adaptive immunity specific CD4+ and CD8+ T cells: a new role - Activation of influenza virus (2013) (0)
- Ion Efflux and Influenza Infection Trigger NLRP3 Inflammasome Signaling in Human Dendritic Cells (2015) (0)
- CD11b/CD18 ligation on monocyte-derived dendritic cells dampens human Th17 cell responses (52.6) (2012) (0)
- Chapter 23 – Dendritic Cell Biology (2018) (0)
- Cancer Immunity (12 July 2007) Vol. 7, p. 11 (2005) (0)
- Abstract 1379: Discovery of tumor-associated, immunogenic peptides presented in a patient-derived, mutant calreticulin-driven myeloproliferative neoplasm cell line (2022) (0)
- 555 Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients (2022) (0)
- Abstract B169: Matrix metalloproteinase-2 and Toll-like receptors modulating immune responses in the tumor microenvironment (2016) (0)
- Effect of matrix metalloproteinase-2 on antitumor immunity. (2012) (0)
- Personalized neoantigen vaccination with synthetic long peptides (2014) (0)
- Modulating innate immune mechanisms to improve anti- tumor immunity. (2017) (0)
- Use of gene expression profile and mitotic index of metastatic melanoma lesions as an adjunct to TNM staging in predicting patient survival. (2009) (0)
- Abstract B161: Mechanisms underlying the induction of natural killer cell exhaustion in metastatic melanoma (2016) (0)
- Flt3L-primed in situ vaccine for patients with low-grade lymphoma: tumor regression at untreated sites (NCT01976585) (2014) (0)
- EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer (2018) (0)
- UV-Inactivated , Recombinant EBNA-3 A Vaccinia Virus Responses Using Dendritic Cells Pulsed With EBNA-3 A Peptides or Induction of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocyte (1999) (0)
- Gene expression profile for metastatic melanoma and patient survival (2008) (0)
- ATIM-31. PHASE I STUDY OF TUMOR TREATMENT FIELDS AND A PERSONALIZED MUTATION-DERIVED TUMOR VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2018) (0)
- Maturation of Human Dendritic Cells in Heat Shock Proteins and Induce the Primary Tumor Tissue Lysates Are Enriched (2013) (0)
- Effect of matrix metalloproteinase-2 on CD8+ T cell and NK cell responses. (2012) (0)
- Antitumor immunity as the basis for durable disease-free, treatment-free survival (DDFTFS) in patients with metastatic urothelial cancer (mUC). (2023) (0)
- Abstract B157: Modulation of natural killer cell dysfunction in human bladder cancer (2019) (0)
- Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma (2015) (0)
- Abstract SY14-02: Personalized therapies: Neoantigen discovery and vaccination (2018) (0)
- 334 Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients (2021) (0)
- Abstract A077: Unraveling predicted immunomodulatory effects of novel cancer-associated noncoding RNAs (2016) (0)
- Transfection of dendritic cells (DCs) with mRNA encoding IL-12p70 enhances anti-tumor immunity in melanoma patients (2008) (0)
- 62 Resistance to frameshift neoantigen-specific T cell surveillance in microsatellite unstable cancers (2022) (0)
- Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells (2020) (0)
- Reply to Murali and Scolyer: Immune profile and mitotic index in advanced melanoma (2010) (0)
- Activation of Toll-like Rec eptor-2 by Endogenous Matrix Metalloproteinase-2 Modulates Dendritic-Cell-Mediated Inflammatory Responses Graphical (2014) (0)
- Matrix metalloproteinase-23 as a new immunotherapeutic checkpoint target in melanoma. (2014) (0)
- Abstract B108: Molecular and cellular properties of neoantigen-specific CD8+ T-cells on interaction with B16F10 melanoma in situ (2019) (0)
- Author Correction: A conserved dendritic-cell regulatory program limits antitumour immunity (2020) (0)
- Vaccinationwith Recombinant NY-ESO-1 Protein Elicits Immunodominant HLA-DR 52 b-restricted CD 4 + TCell Responses with a Conserved TCell Receptor Repertoire (2009) (0)
- Abstract SY03-03: Modulating innate and adaptive immunity through the manipulation of dendritic cells (2010) (0)
- Abstract 5587: Characterization of shared immunogenic frameshift mutations in microsatellite unstable cancers to guide the design of off-the-shelf immunotherapies (2020) (0)
- Unraveling predicted immunomodulatory effects of novel cancer-associated non-coding RNAs (2015) (0)
- T Cells + Memory CD8 Efficient Activation of Influenza A-Specific Requirement of Mature Dendritic Cells for (2000) (0)
- Abstract 531: The landscape of immunostimulatory RNA transcription (2016) (0)
- Uncloaking Breast Tumor Neoantigens with Radiation. (2021) (0)
- Tumor Infiltrating Myeloid Cells Confer de novo Resistance to PD-L1 Blockade through EMT-stromal and Tgf-beta Dependent Mechanisms. (2022) (0)
- Abstract A005: A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers (2019) (0)
- Memory CD8+ T Cells Efficient Activation of Influenza A-Specific Requirement of Mature Dendritic Cells for (2013) (0)
- Abstract 2178: Circulating tumor DNA (ctDNA) correlates closely with tumor necrosis and relapse-free survival (RFS) in hepatocellular carcinoma (HCC) patients treated with perioperative cemiplimab (2023) (0)
- Harnessing the unique immune biology of cytomegalovirus for cancer immunotherapy (2022) (0)
- P10-05. Suppression of human dendritic cell function during acute HIV infection (2009) (0)
- Shared tumor antigens in uterine cancers with microsatellite instability: Putative targets for immunotherapeutic approaches (2019) (0)
- Abstract A087: Quantifying the landscape of immunostimulatory tumoral RNA (2016) (0)
- 444 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination (2020) (0)
- Abstract LB-081: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapy (2016) (0)
- Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (0)
- MP57-19 TIM-3 AND TIGIT ARE POTENTIAL IMMUNE CHECKPOINT TARGETS IN PATIENTS WITH BLADDER CANCER (2019) (0)
- Chapter 75 The initiation of cell-mediated immune responses (1992) (0)
- Use of KBMA Listeria monocytogenes as an antigen loading platform for dendritic cell-mediated induction of antitumor immunity (2008) (0)
- Advancing scientific knowledge in times of pandemics (2020) (0)
- Abstract IA24: Vaccines targeting innate immune cells (2015) (0)
- MP66-19 SURVEY OF B AND PLASMA CELLS IN BLADDER CANCER (2021) (0)
- Activation of Toll-like receptor-2 by tumor associated matrix metalloproteinase-2 modulates dendritic cell function (2014) (0)
- Method and composition for the production of mature dendritic cells (1998) (0)
- Characterization of urine-derived immune cells from bladder cancer patients and comparison to tumor and peripheral blood (2022) (0)
- Microparticles and Apoptotic Cells Generated from Apoptotic T Cells Inhibit Human Dendritic Cell Cytokine Production (2008) (0)
- 946 Dissecting myeloid cell-mediated mechanisms of resistance to immune checkpoint blockade in bladder cancer (2022) (0)
- A Novel In Situ Vaccine: Intratumoral Flt3L and Poly-ICLC with Low-Dose Radiotherapy (2016) (0)
- PD12-04 SURVEY OF B AND PLASMA CELLS IN BLADDER CANCER ACROSS TUMOR MICROENVIRONMENTS (2022) (0)
- Abstract B080: Improved neoantigen vaccine selection by combining prediction of pMHC presentation and T-cell epitopes (2019) (0)
- 82 Single-cell RNA sequencing and CITE-Seq analysis of bladder cancer patient urine with matched tumor and peripheral blood suggests urine as a window into the tumor immune microenvironment (2021) (0)
- Abstract 3210: Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA) (2020) (0)
- Massive monoclonal expansion of functionally stable human regulatory T cells (THER5P.826) (2014) (0)
- Immune gene expression in primary melanomas to predict lower risk of recurrence and death. (2013) (0)
- EP1.04-15 NSCLC Response Determinants to Chemoimmunotherapy: Deep Profiling of Tumors Following Neoadjuvant Cemiplimab and Chemotherapy (2019) (0)
- P16-52. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism (2009) (0)
- in Mediating the Terminal Maturation of Human Dendritic Cells A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines (2013) (0)
- The initiation of cell-mediated immune responses (1992) (0)
- HIV triggers immunoregulatory dendritic cells and regulatory T cells through the non-canonical NF-kB pathway (2012) (0)
- Abstract SY22-02: Personalized cancer vaccines: Antigen selection and translation into the clinic (2021) (0)
- Abstract A104: Matrix metalloproteinase-2 and Toll-Like receptors modulating immune responses in the tumor microenvironment (2019) (0)
- Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (0)
- Apoptotic microparticles generated during acute HIV-1 infection inhibit human dendritic cells via CD44 (2012) (0)
- Melanoma progression is associated with NK cell exhaustion (2014) (0)
- Abstract 5648: Single cell spatial phenotyping of bladder tumors with a novel mechanism of NKG2A and HLA-E mediated resistance to BCG immunotherapy (2023) (0)
- 364 Antigen abundance and TCR avidity impact T cell-mediated tumor recognition in novel B16F10 ACT model (2022) (0)
- A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles (2020) (0)
- Structural Basis for Self-Discrimination by Neoantigen-Specific TCRs (2023) (0)
- FunctionAssociated with Diminished Dendritic Cell The Anergic State in Sarcoidosis Is (2008) (0)
- Abstract LB-252: Matrix metalloproteinase-2 dysregulate anti-tumor immunity (2014) (0)
- Retrospective cohort analysis of adjuvant NY-ESO-1 vaccines in stage III melanoma. (2016) (0)
- Martin A. “Mac” Cheever, MD: In Memoriam (1944–2021) (2021) (0)
- Human Immunodeficiency Virus Type 1 Modified To Package Simian Immunodeficiency Virus Vpx Efficiently Infects Macrophages and Dendritic Cells (cid:1) † (2011) (0)
- Crossprocessing and Crosspresentation (2008) (0)
- Clinical relevance of neutral endopeptidase overexpression in melanoma. (2006) (0)
- Dysregulation of antimelanoma immunity by the matrix metalloproteinase-2 enzyme (2013) (0)
- TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer (2023) (0)
- A conserved dendritic-cell regulatory program limits antitumour immunity (2020) (0)
- Clinical development strategy of immunotherapy combination (2020) (0)
- Small amounts of superantigen on dendritic cells are sufficient to initiate T cell responses (2020) (0)
- 772 MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination (2021) (0)
- Abstract SY40-02: Interplay between microenvironment and cancers (2012) (0)
- Abstract CT096: Phase I study of in situ autologous vaccination for prostate cancer in a neo-adjuvant setting (2019) (0)
- 9 – Dendritic Cells (2013) (0)
- Abstract A191: Novel approaches to the study of NK cell exhaustion in humans (2019) (0)
- 559 Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 PORTER platform trial in metastatic castration-resistant prostate cancer patients (2022) (0)
- Elevated HLA-E and NKG2A as a Consequence of Chronic Immune Activation Defines Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer (2022) (0)
- Abstract 1313: Genomic and transcriptomic profiles of primary prostate cancer identify unique targets for therapeutic intervention (2020) (0)
- Apoptotic microparticles generated during acute HIV-1 infection inhibit human dendritic cells via CD44 (2012) (0)
- Targeting HLA-E for prostate cancer immunotherapy (2018) (0)
- 289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting (2020) (0)
- NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer (2022) (0)
- Dead-cell-associated proteins are an important source of antigens for cross-presentation by dendritic cells (2004) (0)
- NK cell dysregulation in metastatic melanoma. (2011) (0)
- Impact of immune modulation on sentinel lymph node positivity and outcome in melanoma patients. (2011) (0)
- Abstract 465: Characterization of NK cell exhaustion in melanoma at different stages. (2013) (0)
- Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma. (2015) (0)
- Abstract B072: Immune checkpoint blockade enhances mutated calreticulin-induced T-cell immunity in myeloproliferative neoplasms (2019) (0)
- Abstract CT205: A phase I/Ib trial of intratumoral Poly-ICLC in resectable malignant pleural mesothelioma (2022) (0)
- Natural pattern-recognition-receptor agonists in prophylactic vaccines for in situ vaccination of lymphoma. (2016) (0)
- Abstract 253: Analyses of tumor-specific T cell dynamics and tumor immune contexture in microsatellite instability-high cancers in response to first-line therapy (2022) (0)
- Abstract A109: Matrix metalloproteinase-2 stimulates Toll-like receptor-2 on melanoma cells to induce immunosuppressive inflammation in the tumor microenvironment (2019) (0)
- C106 Distinguishing Features of Transmitted/Founder HIV-1 (2013) (0)
- Defining the transcriptional landscape of infiltrating immune cells in human and mouse bladder cancer (2020) (0)
- A pilot trial evaluating the rapid sequencing of approved therapies in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC). (2023) (0)
- Effect of TLR4 engagement on TLR3-induced proinflammatory signaling in dendritic cells through IL-10, STAT3, and p38-dependent pathways and on antimelanoma CD8+ T-cell priming. (2010) (0)
- Corrigendum to “Efficient in vitro expansion of JC virus-specific CD8+ T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy” [Virology 383 (2009) 173–177] (2010) (0)
- of Immune Evasion Human Dendritic Cells: A Novel Mechanism Vaccinia Virus Inhibits the Maturation of (1999) (0)
- Association of natural killer (NK) cell exhaustion with melanoma progression. (2014) (0)
- Abstract B032: PhIP-seq assessment of the serum antibody repertoire before and after immune-related adverse events in four melanoma patients treated with checkpoint blockade immunotherapy (2019) (0)
- HIV triggers immunoregulatory dendritic cells and regulatory T cells through the non-canonical NF-kB pathway (2012) (0)
- Ion efflux and influenza infection trigger NLRP3 inflammasome signaling in human dendritic cell (VIR5P.1148) (2015) (0)
- Abstract IA31: Measuring the emergence of non-self in tumors (2019) (0)
- EPCO-22. IDENTIFYING NEOANTIGENS FOR A PERSONALIZED MUTATION-DERIVED GENOMIC VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2020) (0)
- Blood Dendritic Cell Subsets in Early HIV Infection (2008) (0)
- 314 NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer (2021) (0)
- Abstract CT270: Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting (2023) (0)
- 3355 Peripheral natural killer (NK) cell phenotype and soluble MHC class I chain-related gene (sMICA) are potential prognostic markers in melanoma (2015) (0)
- Track B Clinical Science (2012) (0)
- Abstract B160: Matrix metalloproteinase-2 modulates inflammation and melanoma progression via TLR2 (2016) (0)
- Abstract 457: Matrix metalloproteinase-2 modulates antitumor immunity. (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Nina Bhardwaj?
Nina Bhardwaj is affiliated with the following schools:
